Compile Data Set for Download or QSAR
Report error Found 146 Enz. Inhib. hit(s) with all data for entry = 6508
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134531(US8846656, 23-I)
Affinity DataIC50: 0.5nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134505(US8846656, 21-D)
Affinity DataIC50: 0.5nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134512(US8846656, 21-R)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134530(US8846656, 23-H)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134519(US8846656, 21-AH)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134518(US8846656, 21-AG)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134500(US8846656, 19-AF)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134511(US8846656, 21-Q)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134574(US8846656, 55-I)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134520(US8846656, 21-AI)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134569(US8846656, 52-C)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134577(US8846656, 55-M)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134580(US8846656, 56-C)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134582(US8846656, 56-F)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134524(US8846656, 21-AM)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134523(US8846656, 21-AL)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134586(US8846656, 65-A)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134596(US8846656, 69-L)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134589(US8846656, 65-I)
Affinity DataIC50: 1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134546(US8846656, 29)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134525(US8846656, 22-C)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134571(US8846656, 54-B)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134479(US8846656, 17-AM)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134529(US8846656, 23-G)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134498(US8846656, 19-AD)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134502(US8846656, 19-AI)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134551(US8846656, 32-B)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134572(US8846656, 55-G)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134579(US8846656, 56-B)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134509(US8846656, 21-N)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134507(US8846656, 21-K)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134581(US8846656, 56-E)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134591(US8846656, 68-B)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134587(US8846656, 65-B)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134590(US8846656, 65-K)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134601(US8846656, 71-B)
Affinity DataIC50: 2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134576(US8846656, 55-L)
Affinity DataIC50: 3nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134544(US8846656, 28-B)
Affinity DataIC50: 3nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134562(US8846656, 41-G)
Affinity DataIC50: 3nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134490(US8846656, 19-F)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134517(US8846656, 21-AF)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134499(US8846656, 19-AE)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134470(US8846656, 17-G)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134497(US8846656, 19-AC)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134545(US8846656, 28-D)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134501(US8846656, 19-AH)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134515(US8846656, 21-AB)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134573(US8846656, 55-H)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134572(US8846656, 55-G)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Novartis

US Patent
LigandPNGBDBM134593(US8846656, 69-H)
Affinity DataIC50: 4nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/9/2015
Entry Details
Go to US Patent

Displayed 1 to 50 (of 146 total ) | Next | Last >>
Jump to: